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AbstrACt
Introduction X- linked hypophosphataemic rickets/
osteomalacia (XLH) is a chronic, debilitating genetic 
disease characterised by skeletal abnormalities and 
growth disorder. The burden of XLH begins in childhood 
and continues throughout life. Conventional medical 
therapy with phosphate, active vitamin D and surgery 
do not address the underlying pathophysiology of the 
disease. While treatment during childhood may improve 
bone deformity and growth retardation, a large proportion 
of adult patients still fail to reach normal stature. 
Furthermore, adult patients with XLH report comorbidities 
associated with unresolved childhood disease, as well 
as newly developed disease- related complications and 
significantly impaired quality of life (QOL). Despite the 
multiple negative aspects of XLH, Asian consensus 
statements for diagnosis and management are lacking.
Methods and analysis The Study of longitUdinal 
observatioN For patients with X- Linked 
hypOphosphataemic rickets/osteomalacia in 
collaboration With Asian partnERs study is a longitudinal 
observational cohort study of patients with XLH, 
designed to determine the medical characteristics 
and burdens (physical, emotional and financial) of this 
progressive disease and to evaluate the impact of 
treatment (including the use of burosumab) on clinical 
outcomes. The study was initiated in April 2018, and 
registration will remain open until 30 April 2022. The 
sample size planned for analyses is 160 patients, 
consisting of 100 patients in Japan and 60 patients 
in Korea. Up to 5 years of observation are planned 
per patient, from enrolment through to April 2023. 
Prospective and retrospective data will be collected 
to evaluate variables, including height/growth, rickets 
severity score, QOL, motor function and biomarkers for 
phosphate metabolism and bone turnover.
Ethics and dissemination Ethics approval was 
obtained from the Ethics Committee of Osaka University, 
the Ethics Committee of Kyowa Kirin Co and by the 
Ethics Committee of each participating medical 
institution. Two interim analyses and associated 
publications are planned using retrospective and 
enrolment data at year 1 and results at year 3.
trial registration numbers NCT03745521; 
UMIN000031605.
IntroduCtIon
X- linked hypophosphataemic rickets/osteo-
malacia (XLH) is a rare, serious, debilitating, 
strengths and limitations of this study
 ► The SUNFLOWER (Study of longitUdinal obser-
vatioN For patients with X- Linked hypOphospha-
taemic rickets/osteomalacia in collaboration With 
Asian partnERs) study was designed to determine 
the medical characteristics and natural course of 
X- linked hypophosphataemic rickets/osteomalacia 
(XLH); to determine the physical, psychological and 
economic burden of XLH through long- term obser-
vation, and to evaluate treatment efficacy and safety.
 ► Only patients with a confirmed diagnosis of XLH will 
be included, many of whom are likely to have re-
ceived at least some treatment for their condition; 
therefore, examination of the disease process in un-
treated patients may be limited, depending on data 
availability.
 ► Undiagnosed patients with fewer or less severe 
clinical manifestations may be unaware of their XLH 
status; thus, although the study has no restrictions 
on enrolment according to stage or severity, cases 
with a mild disease phenotype may be poorly repre-
sented in the analysis, potentially resulting in a bias 
towards more severe forms of the disease.
 ► This study will be conducted in Japanese and Korean 
patients only, and we cannot exclude the possibility 
that disease characteristics may vary according to 
ethnicity, potentially confounding the ability to ex-
trapolate the study data to XLH patient populations 
in other countries.
 ► As the largest multicentre cohort of XLH patients 
evaluated in Asia to date, the SUNFLOWER study 
will be critical to advancing our knowledge of this 
debilitating disease, and it is hoped that the data 
accrued may contribute to future global consensus 
guidelines for XLH diagnosis and management.
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chronic genetic disease, with an incidence of approximately 
1 in 20 000 people.1–3 XLH is inherited in an X- linked domi-
nant pattern and results from inactivating mutations of the 
phosphate- regulating gene with homologies to endopepti-
dases on the X chromosome (PHEX).4 Impaired function 
of PHEX protein is believed to cause XLH5 and, to date, 
>300 different PHEX gene mutations have been identified 
in patients with XLH.6–8 XLH is the most common form of 
inherited rickets and is characterised by renal phosphate 
wasting with subsequent hypophosphataemia, impaired 
bone mineralisation, impaired endochondral ossification 
in the growth plate and bone deformities.6 9 10 Hypophos-
phataemia occurs in patients with XLH owing to elevated 
levels of FGF23.6 11 12 However, the exact mechanism by 
which PHEX dysfunction results in an increase in FGF23 is 
complex and is not yet fully understood.5 6 13
The burden of XLH begins in childhood, with signifi-
cant levels of pain and impaired physical functioning, and 
continues throughout life14; adults with XLH have comor-
bidities associated with unresolved childhood disease, 
as well as newly developed disease- related problems.14 15 
Skeletal abnormalities (eg, bowing deformities of the legs) 
and growth disorder commonly appear in late infancy and 
may result in short stature through adulthood.6 10 16 Chil-
dren with XLH often develop dental problems such as 
spontaneous dental abscesses.15 Adult patients with XLH 
have increased disability, musculoskeletal pain and risk of 
active fractures (including pseudofractures), joint abnor-
mality and enthesopathies (eg, spinal ligament ossifica-
tion),5 6 and they may suffer from hearing impairment and 
dental problems.17 18 Furthermore, complications such as 
craniosynostosis in children and Chiari I malformations in 
both children and adults have also been reported in XLH 
patients.19–21 However, despite the major impacts of XLH 
on patient functioning, quality of life (QOL) data in this 
patient population are scarce. One prospective study in 
52 adult patients reported that QOL associated with XLH 
was worse than that associated with axial spondyloarthritis, 
a disease with a high functional disability; the presence 
of musculoskeletal and dental complications in XLH was 
significantly associated with worse QOL scores.17 A recent 
burden of disease survey reported that the clinical manifes-
tations of XLH place a substantial burden on children with 
the disease and that this burden continues into adulthood, 
resulting in a lifelong detriment to health.14
Long- term outcomes of patients with XLH are depen-
dent on early diagnosis and timely initiation of therapeutic 
management.22 Treatment goals are to reduce bone defor-
mity and increase height in children, relieve pain in adults 
and improve osteomalacia and healing of active fractures 
(including pseudofractures).5 However, despite treat-
ment with active vitamin D analogues and phosphate salts, 
disease manifestations may be insufficiently controlled,17 
and some patients with XLH may require surgical correc-
tion for limb deformity, spinal decompression and joint 
replacement.18 23 24 Furthermore, although appropriate 
conventional pharmacological treatment from childhood 
can improve growth, it does not result in normalisation of 
adult height in a large proportion of patients.15 Previous 
observational studies of XLH have evaluated the association 
between lack of treatment in childhood and an increase in 
complications in adulthood.25 26 However, because of the 
small number of patients in individual studies, owing to the 
scarcity of XLH, only limited conclusions can be drawn. 
Furthermore, there is little information on treatment poli-
cies among medical institutions and regions/countries. 
Although a few clinicians’ guides have been published5 15 22 
and a diagnostic flowchart for FGF23- related hypophos-
phataemic diseases (which includes XLH) was proposed 
in Japan,27 the lack of global consensus guidelines might 
result in heterogeneous and potentially suboptimal disease 
management. Recently, a group of European clinicians 
published clinical practice recommendations for the diag-
nosis and management of XLH, and claimed that ‘knowl-
edge about this condition is unfortunately often restricted 
to a few specialised centres’.28 Thus, it is evident that a wide-
spread clinical understanding of XLH is lacking, and addi-
tional disease information is needed to inform physicians 
in this field with the ultimate aim of developing globally 
accepted guidelines for XLH diagnosis and management.
Owing to the widespread lack of accord regarding the 
disease course and optimal management techniques 
in Asia, there is a clear need for observational studies 
providing clinical information on the changing character-
istics of this disease over time. The SUNFLOWER (Study 
of longitUdinal observatioN For patients with X- Linked 
hypOphosphataemic rickets/osteomalacia in collaboration 
With Asian partnERs) study was designed to determine the 
medical characteristics and natural course of the disease; 
to determine the physical, psychological and economic 
burden of XLH through long- term (up to 5 years) obser-
vation of patients and to evaluate treatment efficacy and 
safety in patients with XLH. In addition to the prespecified, 
observational measurements obtained during the study, 
retrospective data will also be collected, which will enable 
us to produce a detailed picture of the XLH disease process 
across long periods. This study should expand the foun-
dations of our knowledge of the clinical picture across the 
XLH disease severity spectrum. Assessing which patients 
need treatment, when to give treatment and what drugs are 
most appropriate will be the future research questions that 
will be considered using the data set obtained in this study. 
It is hoped that the information accrued during this study 
will contribute significantly to developing a future global 
consensus guideline for XLH diagnosis and management.
MEthods And AnAlysIs
design and setting
The SUNFLOWER study is a longitudinal observational 
cohort study of patients with XLH. The study was initiated 
in April 2018, and registration will remain open until 30 
April 2022. Up to 5 years of observation are planned per 
patient, from enrolment through to April 2023. The study 
will initially be conducted in Japan and Korea. However, 
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Figure 1 Objectives and exploratory analysis in the 
longitudinal, observational Study of longitUdinal observatioN 
For patients with X- Linked hypOphosphataemic rickets/
osteomalacia in collaboration With Asian partnERs study. 
QOL, quality of life.
additional regions may subsequently be included if it 
becomes necessary to increase the accrual rate.
target population and sample size
All outpatients, including adults and children, with XLH 
at each study centre, who have given consent (or whose 
parents/guardians have given consent for patients aged 
<20 years (Japan) or <19 years (Korea)) to participate 
in the study, will be enrolled. In order to collect general 
data on XLH, no inclusion/exclusion criteria based on 
the stage or severity of the disease have been established; 
thus, data from patients with symptoms ranging from 
mild to severe should be available for analysis.
The sample size planned for analyses is 160 patients, 
consisting of 100 patients in Japan and 60 patients in 
Korea. The sample size was determined based on feasi-
bility and the number of potential XLH outpatients that 
can be enrolled in participating medical institutions. 
Owing to the lack of evidence from prior research and 
the scarcity of relevant information, no calculations for 
sample size or statistical power were conducted.
Inclusion criteria
The study population will include patients of any age 
who have been clinically diagnosed with XLH, and who 
have one or more of the following: a documented PHEX 
mutation, at least one family member with a documented 
PHEX mutation or a documented intact FGF23 level 
>30 pg/mL (cut- off value for diagnosing FGF23- related 
hypophosphataemia29; measured by Kainos Laboratories, 
Tokyo, Japan). Participants must also have a history or 
current physical signs of rickets/osteomalacia, regardless 
of treatment history (presence/absence of treatment or 
type of treatment). The retrospective data will be used 
to determine a history of osteomalacia based on the defi-
nition of osteomalacia stated in the Diagnosis Manual of 
Rickets and Osteomalacia.30
Exclusion criteria
Study exclusion criteria are participation in another clin-
ical study at the time of informed consent (participation 
in this study will be allowed after completion of any other 
relevant clinical study) and presence of any characteristic 
that may make participation inappropriate or unsafe.
outcomes
In figure 1, we describe the objectives of the SUNFLOWER 
study, the specific clinicopathological areas of interest and 
the information that will be collected and evaluated. For 
patients aged <18 years, primary study outcome measures 
are assessments of height, rickets severity score,31 QOL 
and motor function. For patients aged ≥18 years, primary 
study outcome measures are QOL and motor function 
assessment.
For patients aged <18 years, secondary outcome 
measures include measurements of growth velocity, lower 
limb deformity, biomarkers for phosphate metabolism and 
bone turnover and frequency of active fractures (including 
pseudofractures). For patients aged ≥18 years, secondary 
outcome measures include measurement of biomarkers 
for phosphate metabolism and bone turnover, frequency 
of active fractures (including pseudofractures), spinal liga-
ment ossification, nephrocalcinosis and renal function. To 
adequately evaluate a pseudofracture, the participating 
institution will be requested to provide imaging data, such 
as radiographs, CT images and MRI, and the registered 
data will be evaluated by the Central Evaluation Committee 
consisting of orthopaedic surgeons and radiologists. If a 
study patient presents a fracture, the attending physician 
will fill out an evaluation form in which the fracture will be 
classified as traumatic or non- traumatic.
data collection
Due to the nature of the research design, interventions 
will not be mandated as part of the study. Based on routine 
clinical practice, specified assessments will be conducted 
annually in patients aged <18 years and every 2 years in 
patients aged ≥18 years (figure 2). A schedule of assess-
ments showing the procedures and measurements taken 
for patients aged <18 and ≥18 years (including those who 
receive treatment with burosumab, a new drug to be 
launched for the treatment of XLH) is shown in table 1. 
Patients aged <18 years will undergo measurements of 
sitting height, arm length and leg length, height and body 
weight, among other assessments. For patients aged ≥18 
years, data will be collected on the treatment received for 
the underlying disease and its complications, and bone 
mineral density, among other parameters. For patients 
aged ≥18 years, bone mineral density will be measured by 
dual- energy X- ray absorptiometry (site of measurement: 
hip, lumbar spine, or other).
For patients who start the treatment with burosumab 
during the study, observation, examination and assess-
ments will be performed before the start of treatment 
with burosumab, at 3 months, 6 months, 1 year and once 
a year thereafter for patients aged <18 years, and every 2 
years for patients aged ≥18 years. For patients who have 
received burosumab before participation in the study, 
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Figure 2 Schematic of study flow.
Assessments
Observation, examination and assessment items include 
demographic and baseline characteristics, radiographs 
(images of wrists, knees and leg long bones), ultraso-
nograms, dental assessment, surgical or medication 
requirements for the underlying disease, disease- related 
complications, laboratory tests, motor function (≥5 
years to <18 years: 6- min walk test (6MWT),32 ≥18 years: 
timed up and go test (TUGT)33 and grip strength), loss 
of working/learning opportunities and serious adverse 
events. Safety in terms of renal function will also be 
evaluated by serum and urine analysis and renal ultra-
sonography; however, as this is an observational study, 
management of safety events will not be performed by the 
study investigators. Adverse events will be managed by the 
treating physician according to their judgement. Retro-
spective data will also be collected for some parameters, 
including height, body weight, Tanner stage (patients 
aged <18 years), previous treatment and history of active 
fractures (including pseudofractures).
Disease-related and treatment-related complications
The date of onset for the following disease- related compli-
cations will be collected: femoral curvature, tibial/fibular 
curvature, genu varum, pigeon- toed gait, genu valgum, 
abnormal gait/running, leg length discrepancy, coxa vara, 
spinal canal stenosis, renal calculus, nephrocalcinosis, 
hypertension, chronic kidney disease (stage 3–5), haemo-
dialysis, Chiari malformation, syringomyelia, increased 
intracranial pressure, deafness, tinnitus, dizziness, hyper-
calciuria, hypercalcaemia, hyperparathyroidism and 
others. For bone pain, arthralgia, osteoarthritis, joint stiff-
ness, osteophyte formation, enthesopathy, spinal canal 
stenosis, ossification of posterior longitudinal ligament, 
ossification of anterior longitudinal ligament and ossifica-
tion of yellow ligament, in addition to the date of onset, 
the site of onset will also be collected.
Laboratory assessments
Blood and urine sampling will be performed at least 
4 hours after a meal or intake of a phosphate preparation. 
Blood chemistry evaluations will include FGF23, phos-
phate, calcium, albumin, intact parathyroid hormone, 
1,25- dihydroxyvitamin D, 25- hydroxyvitamin D, alka-
line phosphatase, bone- specific alkaline phosphatase, 
creatinine and blood urea nitrogen. Urinalysis will be 
performed to evaluate phosphate, calcium, albumin and 
creatinine levels.
Functional assessments
As leg length may be a potential predictor of future 
height,24 annual anthropometric measurements (height, 
leg length, arm length and sitting height to a maximum 
extent) performed in patients aged <18 years (during the 
growth stage) will be used to investigate the efficacy of 
XLH treatment during the long- term observation period.
In addition to the skeletal defects occurring in patients 
with XLH, dental health is also affected due to defective 
mineralisation,34 commonly resulting in dental defects, 
abscesses and periodontitis.5 35 Study assessments will, 
therefore, include presence or absence of disease mani-
festations such as dental caries, dental abscess, gingivitis 
and permanent tooth extraction, along with the number 
of affected teeth if there are sufficient evaluable data 
available.
Patients often have compromised ambulatory ability 
and impaired handgrip strength, among other func-
tional problems.5 6 36 Changes in walking ability over time 
will be assessed using the 6MWT and the TUGT, which 
provide means to measure functional exercise capacity in 
children and adults, respectively.33 37 Handgrip strength 
(both hands in a sitting position), which is also associ-
ated with mobility and physical functioning,38 will also be 
evaluated.
Qol assessment
QOL and economic burden (impact on ability to work/
learn) will be assessed using questionnaire- based patient- 
reported outcome (PRO) measures, including a PRO 
measurement information system (all ages),39 10- item 
short- form health survey for children (<18 years),40 revised 
faces pain scale (<18 years),41 EuroQol 5- dimensions 
survey (≥8 years),42 Western Ontario and McMaster 
Universities osteoarthritis index (≥18 years)43 and brief 
pain inventory (≥18 years).44 PRO data concerning 
working/learning will be collected annually in patients 
aged <18 years and every 2 years for patients aged ≥18 
years, and a specifically prepared assessment sheet will be 
used for patients who are elementary school- aged chil-
dren or older.
statistical analyses
Study data will be analysed in an exploratory manner 
appropriate to an observational study. Categorical vari-
ables will be described by frequency and proportion; 
summary statistics (number of patients, mean, SD, 
minimum, median and maximum) will be used to report 
continuous data. Details of all analyses will be specified 
in the Statistical Analysis Plan (SAP) prepared prior to 
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each analysis time point, including how missing data will 
be handled, and all analyses will be performed in accor-
dance with the SAP.
Patient and public involvement
In contrast with the situation in western countries, there 
are no patient advocacy groups for XLH patients in the 
countries where this study is being conducted. As such, 
patient participation was not realised during the research 
planning stage of this study. However, the medical profes-
sionals (coauthors) who contributed to the development 
of the research plan have extensive clinical experience on 
this disease. Based on the information collected during 
real- world treatment of patients with XLH, the research 
plan was conceived with utmost consideration for XLH 
patients who will be enrolled this study.
EthICs And dIssEMInAtIon
data collection and dissemination
Patients who give written informed consent for partici-
pation in the study will be registered using an electronic 
data capture (EDC) system. Data collected during the 
study will be entered into the EDC. Study investigators 
will be responsible for data input and correction of data.
Two interim analyses are planned using retrospective 
and enrolment data at year 1 (data lock in December 
2019), and results at year 3 (data lock in December 2021). 
The Principal Investigator, the Steering Committee and 
Kyowa Kirin Co will make all decisions about the publi-
cation of the study data. The organisation of the study 
is detailed in online supplementary appendix 1. The 
funding source has no role in the analyses and interpreta-
tion of data to be published.
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